Stock events for Alector, Inc. (ALEC)
Alector's stock price was significantly impacted over the past six months. In November 2025, shares plummeted after the Phase 3 trial of latozinemab (AL001) failed, leading to program discontinuation and workforce reduction. The Q3 2025 earnings reported a net loss of $34.7 million with collaboration revenue declining to $3.3 million. Neil Berkley was appointed as CFO and CBO in December 2025. Q4 2025 earnings reported a quarterly loss of $0.34 per share and revenues of $6.24 million. In February 2026, Wong-Sarad Grace sold 4,079 shares of common stock. As of February 26, 2026, ALEC shares had gained approximately 40.4% since the beginning of the year. An independent interim futility analysis for the PROGRESS-AD study (nivisnebart/AL101) is planned for the first half of 2026.
Demand Seasonality affecting Alector, Inc.’s stock price
As a clinical-stage biotechnology company without commercialized products, Alector, Inc. does not have traditional demand seasonality. Its revenue is primarily derived from collaboration agreements, which are volatile and not subject to seasonal fluctuations.
Overview of Alector, Inc.’s business
Alector, Inc. is a clinical-stage biotechnology company focused on immuno-neurology for neurodegenerative diseases. It operates in the Healthcare sector, specifically Drug Discovery and Biopharmaceuticals, with a pipeline targeting brain immune system dysfunction. Major product candidates include latozinemab (AL001), which failed its Phase 3 trial; nivisnebart (AL101/GSK4527226), in Phase 2 trials; AL137, in preclinical development; AL050, in preclinical development; and AL064, an siRNA program. Alector also utilizes its Alector Brain Carrier (ABC) platform.
ALEC’s Geographic footprint
Alector, Inc. is headquartered in South San Francisco, California, USA. Its operations are global, conducting multinational clinical trials across North America, Europe, Australia, and potentially other regions.
ALEC Corporate Image Assessment
Alector's brand reputation was negatively impacted by the clinical setback of latozinemab (AL001) in November 2025. Despite this, the company is refocusing on its remaining pipeline and ABC platform. Analyst consensus rates ALEC as a "Hold," with a 12-month price target suggesting potential upside. Alector has consistently surpassed consensus EPS estimates over the last four quarters.
Ownership
Alector's ownership is primarily institutional, accounting for 76.47% of shares, with major holders including TCG Crossover Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Individual and insider ownership stands at 42.81%, with Polaris Venture Management Co VI LLC being the largest individual shareholder. Retail investors hold 0.00% of the company's shares.
